Understanding the Mechanisms of SGLT2 Inhibitors in Type 2 Diabetics
Lay Description
Understanding the mechanisms of how the Type 2 Diabetes medication SGLT2 Inhibitor works on glucose production and induces the breakdown of fatty acids.
Category
- Diabetes
- IRB Number
- 20230457HU
- NCT Number
- NCT # not yet entered
Eligibility
- Eligible Ages
- 30-75
- Eligible Genders
- All
- Accepts Healthy Volunteers
Inclusion Criteria
Type 2 Diabetes between the ages = 30-75 y, BMI = 23-38 kg/m2, HbA1c = 7.0-10%, eGFR > 60 ml/min/1.73m2, BP < 145/85 mmHg. Participants must be in general good health. Patients treated with diet, SU, metformin, or SU/MET
Exclusion Criteria
Patients treated with GLP-1 RA, DPP-4i, TZD, or insulin are excluded
Study Design
Arm Groups
Study Contact
Renata Belfort De Aguiar
210-450-3076
belfortda@uthscsa.edu
Andrea Hansis-Diarte
210-567-3208
hansisdiarte@uthscsa.edu
Aurora Merovci
210-567-6691
merovci@uthscsa.edu
Cynthia Ramirez
210-358-7200
ramirezc8@uthscsa.edu
Jessica Shipley
210-567-3208
shipleyj@uthscsa.edu
Principal Investigator
Ralph DeFronzo